Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Income from Continuing Operations (2016 - 2021)

Phio Pharmaceuticals' Income from Continuing Operations history spans 10 years, with the latest figure at 3451000.0 for Q4 2021.

  • For Q4 2021, Income from Continuing Operations fell 40.17% year-over-year to 3451000.0; the TTM value through Dec 2021 reached 13520000.0, down 53.74%, while the annual FY2024 figure was 7387000.0, 31.75% up from the prior year.
  • Income from Continuing Operations reached 3451000.0 in Q4 2021 per PHIO's latest filing, up from 3742000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1493000.0 in Q3 2018 to a low of 5460000.0 in Q1 2017.
  • Average Income from Continuing Operations over 5 years is 2555650.0, with a median of 2330000.0 recorded in 2020.
  • Peak YoY movement for Income from Continuing Operations: tumbled 144.73% in 2017, then skyrocketed 58.99% in 2018.
  • A 5-year view of Income from Continuing Operations shows it stood at 2002000.0 in 2017, then grew by 13.74% to 1727000.0 in 2018, then plummeted by 54.55% to 2669000.0 in 2019, then rose by 7.76% to 2462000.0 in 2020, then plummeted by 40.17% to 3451000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Income from Continuing Operations are 3451000.0 (Q4 2021), 3742000.0 (Q3 2021), and 2687000.0 (Q2 2021).